June 16 (Reuters) - Eli Lilly ( LLY ) is in advanced
talks to acquire gene editing startup Verve Therapeutics ( VERV )
for up to $1.3 billion, the Financial Times reported on
Monday, citing people familiar with the matter.
Reuters could not immediately verify the report.